retatrutide glp-1 gip glucagon receptor agonist triple Agonism Based Therapies for Obesity Beyond GLP-1: Retatrutide's triple-agonist mechanism

Ethics declarations Competing interests The author declares associations with the following companies: Astra-Zeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, NovoNordisk and Sanofi-Aventis (advisory board membership

While most users arent required to submit blood work, those with diabetes or pre-diabetes are encouraged to upload results for a more tailored evaluation

Regular follow-ups track blood parameters and muscle loss

Advance according to symptoms and medical advice

It's available under two brand names: is Saxenda approved for weight loss in adults and children ages 12 and up with obesity and for adults with overweight plus at least one weight-related condition